Looks like whatever BMY tries with Nivo, Merck are determined to trump them. As surgical techniques get better and better, the advantage of repeat surgery over non-surgical salvage therapies, will get bigger and bigger, and Merck will try and claim the credit with the Keytruda neo-adjuvant. I must look back at your link, because any early deaths may just be indicative of HPD in a minority, in either of these two studies.
News 
Market Data 
Discover 
AI
